{"title":"Brexpiprazole-sertraline combination improves symptoms of PTSD","authors":"","doi":"10.1002/pu.31285","DOIUrl":"https://doi.org/10.1002/pu.31285","url":null,"abstract":"<p>Combination treatment with brexpiprazole and sertraline was significantly more effective than sertraline plus placebo in reducing symptoms of post-traumatic stress disorder (PTSD) in adults, a Phase 3 study has found. The brexpiprazole-sertraline combination also showed good safety results in line with the safety profile of brexpiprazole. Study results were published online Dec. 18, 2024, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychotropic-induced lipid disturbances","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31286","DOIUrl":"https://doi.org/10.1002/pu.31286","url":null,"abstract":"<p>Use of psychotropic drugs, especially but not only most second-generation antipsychotics, is associated with higher levels of lipids, posing an increased risk for developing cardiovascular disease (Pillinger et al., 2020). There is also evidence that plasma lipid levels and dyslipidemia are substantially impacted by clinical and genetic factors (Ramasamy, 2016).</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psilocybin therapy might help frontline pandemic workers","authors":"","doi":"10.1002/pu.31292","DOIUrl":"https://doi.org/10.1002/pu.31292","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combining lisdexamfetamine and CBT improves outcomes in binge eating disorder","authors":"","doi":"10.1002/pu.31288","DOIUrl":"https://doi.org/10.1002/pu.31288","url":null,"abstract":"<p>Combining lisdexamfetamine and cognitive-behavioral therapy (CBT) reduced binge eating behaviors to a greater extent than the individual treatments alone in patients with binge eating disorder and comorbid obesity, a 12-week randomized trial has found. The combined treatment also led to the greatest reductions in eating disorder psychopathology among the studied treatments.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Guideline includes recommendations for initiating metformin with antipsychotic","authors":"","doi":"10.1002/pu.31289","DOIUrl":"https://doi.org/10.1002/pu.31289","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143533535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stimulants, atomoxetine most efficacious in short term for adult ADHD","authors":"","doi":"10.1002/pu.31295","DOIUrl":"https://doi.org/10.1002/pu.31295","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 4","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychedelics and psychosis: Quantifying the risk","authors":"Lawrence H. Price M.D.","doi":"10.1002/pu.31278","DOIUrl":"https://doi.org/10.1002/pu.31278","url":null,"abstract":"<p>Just over a year ago, I somewhat reluctantly weighed in on the implications for psychiatry of the resurgent interest in psychedelic drugs (Price, 2024). In contrast to the “psychedelic era” of the 1960s and 1970s, this time public interest in these compounds has been accompanied by skillful politico-legal advocacy and systematic research. Both of those endeavors require high levels of funding, and both private philanthropic and for-profit pharmaceutical entities have, for better or worse, stepped in.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Weight-loss drugs improve outcomes in patients with alcohol use disorder","authors":"","doi":"10.1002/pu.31274","DOIUrl":"https://doi.org/10.1002/pu.31274","url":null,"abstract":"<p>Use of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide was associated with reduced risk of alcohol-related hospitalization in patients with alcohol use disorder (AUD), a cohort study has found. Both semaglutide and the GLP-1 receptor agonist liraglutide were associated with lower risk of hospitalization than use of medication treatments for AUD. Study results were published online Nov. 13, 2024, in <i>JAMA Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Meta-analysis suggests safety of methylphenidate, atomoxetine in pregnancy","authors":"","doi":"10.1002/pu.31279","DOIUrl":"https://doi.org/10.1002/pu.31279","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 3","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}